top of page

DR. SAMIR N. KHLEIF

FOUNDER/CEO

Dr. Khleif appears in the Top 100 

Innovators & Entrepreneurs Magazine

Khleif, Samir.jpg

Dr. Samir N. Khleif

Dr. Samir N. Khleif, the founder and CEO of Georgiamune Inc., is a prominent figure in the field of immunotherapy. As a medical oncologist and immunologist, he has made significant contributions to health care and biomedical research.

 

Before assuming his current role at Georgiamune, Dr. Khleif held various academic and leadership positions. One of his notable roles was as a scientist and chief of the NCI Cancer Vaccine Section at the National Cancer Institute (NCI)/National Institutes of Health (NIH). During his tenure, he played a pivotal role in advancing the development of immune-oncology and cancer vaccines, which were subsequently taken to clinical trials.

 

Dr. Khleif's impact extended internationally as he served as the founding director and CEO of the King Hussein Cancer Center in Amman, Jordan. Under his leadership, the center grew into the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center at Augusta University.

 

Currently, Dr. Khleif holds a professorship at Georgetown University Medical School and is recognized as a biomedical scholar. Additionally, he served as a special assistant to the commissioner of the FDA, where he led the FDA's Critical Path Initiative for Oncology. His expertise has also led to his involvement on the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, as well as serving on the scientific advisory boards of over 20 biotechnology and pharmaceutical companies. Dr. Khleif's reputation as an international key opinion leader (KOL) in immunology and immunotherapy is well-established.

 

Georgiamune Inc., the company he founded, specializes in immunotherapeutic biotechnology. It operates as a science and discovery company, focusing on reprogramming the immune system to restore balance and homeostasis for patients with cancer and autoimmune diseases. This approach is considered pioneering and highly differentiated within the field of immunotherapy. The company currently has one therapy in clinical trials and plans to introduce five to six more in the coming two years. Their innovative mechanism has the potential to address various autoimmune diseases.

 

Dr. Khleif's inspiration to start Georgiamune Inc. stemmed from his experience as the director of the Georgia Cancer Center. Recognizing the challenges universities face in developing patents into applications and commercialization, he chose to take matters into his own hands. His goal was to ensure that his discoveries could reach patients and potentially benefit thousands, if not millions.

 

What Dr. Khleif enjoys most about his work includes the thrill of uncovering new aspects of human biology, inventing drugs that can impact human lives, and his passion for building, whether it's cancer centers, hospitals, companies, or other endeavors. His commitment to advancing immunotherapy continues to shape the field and offers hope to patients facing cancer and autoimmune diseases.

 

 

Dr. Samir N. Khleif
Founder and CEO
Georgiamune Inc.

Website: https://www.georgiamune.com/
LinkedIn: https://www.linkedin.com/in/samir-khleif-4280b29/

bottom of page